Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition

Am J Cardiol. 1998 Aug 6;82(3A):25H-30H. doi: 10.1016/s0002-9149(98)00488-3.


The Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) trial is an 8,100 patient, randomized, double-blind, placebo-controlled trial designed to determine the usefulness of angiotensin-converting enzyme (ACE) inhibitors in treating coronary patients with preserved left ventricular ejection fraction. The hypothesis being tested in this trial is that patients with coronary disease and ejection fraction > or =40% who are treated with ACE inhibitors will experience a reduction in the incidence of cardiovascular death, nonfatal myocardial infarction, or a revascularization procedure compared with patients treated with conventional therapy. The design of the PEACE trial is described herein.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Captopril / therapeutic use*
  • Coronary Angiography
  • Coronary Disease / diagnosis
  • Coronary Disease / physiopathology
  • Coronary Disease / prevention & control*
  • Double-Blind Method
  • Echocardiography
  • Enalapril / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Safety
  • Stroke Volume / drug effects
  • Treatment Outcome
  • Ventricular Function, Left / drug effects


  • Angiotensin-Converting Enzyme Inhibitors
  • Enalapril
  • Captopril